Cancer Targeting Therapies: Conventional and Advanced Perspectives

This volume in the popular series, Drugs and the Pharmaceutical Sciences, begins with the history of cancer treatment, carcinogens, and molecular mechanisms involved in cancer pathogenesis. It incudes conventional and advanced cancer therapies ranging from oral and parenteral preparations to advanced fabricated systems such as nanoparticles, liposomes, antibodies, aptamers, poly(amidoamine) and photodynamic therapies. The preparation and mechanisms of molecular targeting of cancer are presented and the authors focus on a diverse audience including undergraduates and research students.

Features

• Timely coverage of changes in process control technology for the phamaceutical industry, a dynamic area in terms of products and manufacturing processes
• Provides an update on the unique requirements of these industries and how they differ from others, for example the microelectronics or specialized chemicals industries
• Draws on the author's vast experience in the field of industrial hygiene and hazardous materials
• Presents a collection of unique situations in which industrial hygiene was implemented to resolve a variety of scenarios and did not interfere with quality issues
• Addresses current topics relating to industry evolution such as migration of therapies to higher potency, RiskMAP, new modalities in medicines and treatments, large molecule therapeutics and conjugates

Dr. Muhammad Yasir Ali

My pharmacy career started back in 2002 as a graduate student, leading to the achievement of a graduate and then a master's degree in Pharmaceutical Technology in 2009. Nevertheless, with my thirst for knowledge as a student and researcher, an in-line experience in production and quality control in Roche Pakistan helped me in knowing the ropes of the subject.

Later on, I joined the university of Lahore as a faculty member and taught different courses to pharmacy graduates, especially pharmaceutical technology. In 2011 after joining my current job, I kept on teaching and indulged myself in research which is still going on, meanwhile, I got my doctorate (Pharmaceutical Technology) from Germany.

I have more than 30 research publications, one research project, practical application of pharmacy knowledge in the form of different marketed products, several book chapters, and one book as editor in my research basket. I got chances of presenting research papers and scientific lectures in different organizations in Germany, USA, UK, and Pakistan.

Dr. Shazia Bukhari

I completed my undergraduate studies from the Bahuddin Zakariya University, Multan (1998-2001) and my M.Phil. studies from the Department of Biochemistry, University of Agriculture, Faisalabad Pakistan (2001-2003). Then I continued higher studies in Punjab University and earned Ph.D. degree in Biochemistry (2005-2009).

I started my career at Hi-Tech Lab, University of Agriculture, Faisalabad (2003 – 2004). Then I joined Center for Agricultural Biochemistry and Biotechnology (CABB), University of Agriculture, Faisalabad as Research Officer/Lecturer (2004-2011). Then I joined Government College University as Assistant Professor (2011-2014). I was promoted to Associate Professor (2014-2019 and Professor (2019 to date) in the Department of Biochemistry of the same university.

My research interest focuses on the exploration of indigenous flora for treatment of various diseases, based on an understanding of the mechanisms underlying the successful interactions between the plant components and disease. For this purpose, we are now using computational tools to correlate the laboratory findings with computer modeling. I am also working to enhance resistance of wheat (Triticum aestivum) against fungus diseases like rust. For this purpose, we have been transforming rust resistance and Pathogenesis-Related genes, isolated from local verities, and transform into high yielding wheat commercial varieties. I have screened and characterized nine novel genes relating rust resistance and pathogenesis related and deposited in gene bank. I am currently running two projects for achieving this goal approved by HEC: 3.679,655 million) as PI and 2^nd approved by Technology Development Funds. HEC (13.609 million) as PI.